Alto Neuroscience FY2023 net loss $36.3M; cash ~$210M post-IPO; Phase 2b MDD studies on track

Alto Neuroscience, Inc.

Net loss $36.3M in FY2023 (vs $27.7M in 2022); R&D spend $30.3M, G&A $7.5M.
Cash $82.5M at Dec 31, 2023; post-IPO net proceeds ~$133M, cash ~$210M as of Feb 29, 2024.
ALTO-100 Phase 2b MDD enrollment ongoing; topline data 2H 2024. ALTO-300 Phase 2b data 1H 2025.
Appointed Drs. Maha Radhakrishnan (ex-Biogen CMO) and Husseini Manji (ex-J&J) to board.
CIRM approved $15M grant for ALTO-100 Phase 2b in bipolar depression; initiation planned 2024 subject to terms.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Alto Neuroscience, Inc. reported financial results for full year ended December 31, 2023.

Period: full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 21, 2024, Alto Neuroscience, Inc. (the "Company") reported financial results for the full year ended December 31, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Alto Neuroscience, Inc. filing history →

Source: SEC EDGAR

accession 0001999480-24-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.